Jefferies Financial Group Inc. Takes $641,000 Position in Myomo, Inc. $MYO

Jefferies Financial Group Inc. bought a new stake in shares of Myomo, Inc. (NYSEAMERICAN:MYO) during the fourth quarter, HoldingsChannel.com reports. The fund bought 704,275 shares of the company’s stock, valued at approximately $641,000.

A number of other hedge funds have also recently modified their holdings of the business. Rosalind Advisors Inc. grew its stake in shares of Myomo by 5.4% during the third quarter. Rosalind Advisors Inc. now owns 3,790,788 shares of the company’s stock valued at $3,381,000 after buying an additional 195,000 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Myomo by 160.8% during the second quarter. Geode Capital Management LLC now owns 669,281 shares of the company’s stock valued at $1,446,000 after buying an additional 412,631 shares during the last quarter. Marshall Wace LLP grew its stake in shares of Myomo by 26.0% during the second quarter. Marshall Wace LLP now owns 304,400 shares of the company’s stock valued at $658,000 after buying an additional 62,743 shares during the last quarter. Centiva Capital LP bought a new position in shares of Myomo during the third quarter valued at approximately $190,000. Finally, Prescott Group Capital Management L.L.C. purchased a new stake in shares of Myomo in the fourth quarter valued at approximately $169,000. Institutional investors own 44.99% of the company’s stock.

Myomo Price Performance

Shares of NYSEAMERICAN MYO opened at $1.09 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.36 and a current ratio of 2.73. The firm has a market capitalization of $42.12 million, a price-to-earnings ratio of -3.03 and a beta of 1.39. The stock has a 50 day moving average price of $0.81 and a 200 day moving average price of $0.85. Myomo, Inc. has a 52-week low of $0.61 and a 52-week high of $3.14.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum reiterated a “buy” rating on shares of Myomo in a report on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $7.67.

Insider Activity at Myomo

In related news, Director Joseph M. Jr. Manko bought 30,367 shares of the stock in a transaction on Friday, May 15th. The stock was bought at an average price of $0.89 per share, for a total transaction of $27,026.63. Following the completion of the acquisition, the director directly owned 2,309,775 shares in the company, valued at approximately $2,055,699.75. This represents a 1.33% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Heather C. Getz bought 70,000 shares of the stock in a transaction on Thursday, March 12th. The shares were bought at an average price of $0.73 per share, with a total value of $51,100.00. Following the acquisition, the director owned 111,754 shares of the company’s stock, valued at $81,580.42. This trade represents a 167.65% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders bought 438,203 shares of company stock worth $358,416. Company insiders own 12.14% of the company’s stock.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.